act legal Switzerland advises on Switzerland's largest financing rounds in 2024

The Swiss Venture Capital Report 2025 documents the growth of the Swiss venture capital market over the past year. act legal Switzerland advised on several of the largest Swiss financing rounds.

The firm advised the lead investors OrbiMed, Novo Holdings, Catalio Nexus Fund, LSP Dementia Fund Coöperatieve U.A. (EQT) and SR One on the two largest financing rounds of 2024:
– Alentis Therapeutics AG – CHF 160 million (Series D financing round)
– Asceneuron AG – CHF 89 million (Series C financing round)

Further transactions included the Series C extension of Memo Therapeutics AG and the USD 147 million Series B extension of Noema Pharma AG, where act legal Switzerland advised the co-lead investors Forbion Growth Opportunities Fund II Coöperatief U.A., Jeito S.L.P. and LSP 7 Coöperatief U.A. (EQT).

The firm also advised the main selling shareholders HBM Healthcare Investments AG, Novo Holdings and Forbion on the USD 1.25 billion spin-off of Yellow Jersey Therapeutics AG, a subsidiary of Numab Therapeutics AG, to Johnson & Johnson.

Our thanks go to the team. Find the full Swiss Venture Capital Report 2025 here.

act legal Switzerland – Mastering Law and Negotiation.